Rudi W Hendriks

Rudi W. Hendriks, PhD is head of the experimental research laboratory of the Department of Pulmonary Medicine of the Erasmus MC. He studied Biology at the University of Utrecht, the Netherlands, and did his PhD studies on X chromosome inactivation patterns in human X-linked immunodeficiency diseases in the Department of Immunohaematology at the Leiden University Medical Center (Prof. J.J. van Rood; Dr. R.K.B. Schuurman) in 1991. After a post-doctoral training in the Genetics Laboratory of the University of Oxford, UK, where he studied genetic aspects of X chromosome inactivation, he received a Royal Academy of Arts and Sciences fellowship and started his own line of research within the lab of Prof. Frank Grosveld at the Department of Cell Biology and Genetics of the Erasmus MC Rotterdam, the Netherlands. In 1999 he moved his group to the Department of Immunology at the Erasmus MC. His research focuses on the molecular biology of the developmental program of B and T lymphocytes, in relation to immunodeficiency diseases and leukemia. The largest effort has gone into the generation of transgenic and knock-out mice to understand the role of signaling molecules in the regulation of cellular proliferation, B cell differentiation and immunoglobulin light chain rearrangement during B cell development. The aims comprise the characterization of signal transduction pathways and lymphoid-specific transcription factors that implement cell fate decisions at specific checkpoints, controlled by antigen receptors and their immature forms. Since Dr. Rudi W. Hendriks moved to the Department of Pulmonary Medicine in 2007, his research is centered on the role of B and T lymphocytes in pulmonary inflammation and immunity.

1. Chen, Z.-Y., Hendriks, R.W., Jobling, M., Powell, J.F., Breakefield, X.O., Sims, K.B. & Craig, I.W. (1992) Isolation and characterization of a candidate gene for Norrie diseases. Nature Genet. 1:204-208.
2. Essers, J., Hendriks, R.W., Swagemakers, S.M.A., Troelstra, C., de Wit, J., Bootsma, D., Hoeijmakers, J.H.J. and Kanaar, R. (1997) Disruption of Mouse RAD54 reduces ionizing radiation resistance and homologous recombination. Cell 89:195-204.
3. Dingjan, G.M., Middendorp. S., Dahlenborg, K., Maas, A., Grosveld, F. and Hendriks, R.W. (2001) Bruton's tyrosine kinase regulates the activation of gene rearrangements at the lambda light chain locus in precursor B cells in the mouse. J. Exp. Med. 193:1169-1178.
4. Kersseboom, R., Middendorp, S., Dingjan, G.M., Dahlenborg, K., Reth, M., Jumaa, H., and Hendriks, R.W. (2003). Bruton’s tyrosine kinase cooperates with the B-cell linker protein SLP-65 as a tumor suppressor in pre-B cells. J. Exp. Med. 198: 91-98.
5. Jumaa, H., Hendriks, R.W. and Reth, M. (2005). B cell signaling and tumorigenesis. Annual Rev. Immunol. 23:415-45.
6. Middendorp, S., Zijlstra, A.E.J., Kersseboom, R., Dingjan, G.M., Jumaa, H. and Hendriks, R.W.  (2005). Tumor suppressor function of Bruton’s tyrosine kinase is independent of its catalytic activity. Blood 105:259-265.
7. De Gorter, D.J.J., Beuling, E.A., Kersseboom, R., Middendorp, S., Van Gils, J.M., Hendriks, R.W., Pals, S.T. and Spaargaren, M. (2007). Bruton’s tyrosine kinase and Phospholipase Cgamma mediate chemokine-controlled B cell migration and homing. Immunity 26: 93-104.
8. Van Loo, P.F., Dingjan, G.M., Maas, A. and Hendriks, R.W. (2007) Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signaling. Immunity. 27:468-680.
9. Ter Brugge, P.J., Ta, V.B.T., DeBruijn, M.J.W., Keijzers, G., VanGent, D.C. and Hendriks, R.W. (2009). A mouse model for chronic lymphocytic leukemia based on expression of the SV40 large T antigen. Blood 115:1385-1393.
10.  Hendriks, R.W. (2011). Btk inhibitor holds promise. Nat Chem Biol. (In press).